Two existing drugs, in combination, have shown significant promise in promoting weight loss, according to a new report.
The drugs, phentermine and Topamax, in combination with lifestyle and weight-loss counseling were associated with a 18-22 pound weight loss in trial participants, compared with a three-pound weight loss in patients who received counseling alone.
The drug also appears to have reduced other obesity-related indicators, such as blood pressure, cholesterol and inflammation levels.
By comparison, the only approved long-term prescription weight loss medication available on the market today, Xenical, is associated with a seven-pound weight loss when combined with diet and exercise.
The study was funded by the pharmaceutical company Vivus, which combined the two drugs into one pill called Qnexa, and petitioned the U.S. Food and Drug Administration for approval in October 2010. The Food and Drug Administration denied the request, asking for more safety data from the company before moving forward.
According to the report, there were specific concerns about each drug's safety individually; specifically Topamax, which is reported to cause some psychiatric and cognitive side effects and may cause clef palate birth defects if taken while pregnant.